EQL Pharma Publishes 2025/2026 Annual Report

EQL Pharma AB, a pharmaceutical company specializing in the development and sale of generic drugs, has published its official annual report for the 2025/2026 financial year. The company's website now hosts the detailed report.

The company currently has 47 niche generics, defined as generics with limited competition beyond the original drug, launched across the Nordic markets. EQL Pharma also maintains a significant pipeline of additional niche generics slated for launch from 2026 onwards. The business operations are focused entirely on prescription drugs, including hospital products, primarily within the Nordics and broader European markets.

With operations based in Lund, EQL Pharma AB is listed on the Nasdaq Stockholm stock exchange. The company engages in extensive development work through collaborations with leading contract manufacturers and major pharmaceutical companies in the EU and Asia.

The annual report provides a comprehensive overview of the company's financial performance, strategic initiatives, and outlook for the period.